241 related articles for article (PubMed ID: 38379333)
1. Molecular complexity of intraductal carcinoma of the prostate.
Zhu S; Xu N; Zeng H
Cancer Med; 2024 Jan; 13(2):e6939. PubMed ID: 38379333
[TBL] [Abstract][Full Text] [Related]
2. Intraductal Carcinoma of the Prostate without High-Grade Invasive Adenocarcinoma: Report of Two Cases and Review of the Literature.
Ortiz-Rey JA; Bellas-Pereira A; San Miguel-Fraile P; Morellón-Baquera R; Domínguez-Arístegui P; González-Carreró Fojón J
Arch Esp Urol; 2022 Nov; 75(9):738-745. PubMed ID: 36472055
[TBL] [Abstract][Full Text] [Related]
3. Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives.
Zong Y; Montironi R; Massari F; Jiang Z; Lopez-Beltran A; Wheeler TM; Scarpelli M; Santoni M; Cimadamore A; Cheng L
Eur Urol Focus; 2021 Sep; 7(5):955-963. PubMed ID: 33132109
[TBL] [Abstract][Full Text] [Related]
4. Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.
Haffner MC; Weier C; Xu MM; Vaghasia A; Gürel B; Gümüşkaya B; Esopi DM; Fedor H; Tan HL; Kulac I; Hicks J; Isaacs WB; Lotan TL; Nelson WG; Yegnasubramanian S; De Marzo AM
J Pathol; 2016 Jan; 238(1):31-41. PubMed ID: 26331372
[TBL] [Abstract][Full Text] [Related]
5. Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate.
Bettendorf O; Schmidt H; Staebler A; Grobholz R; Heinecke A; Boecker W; Hertle L; Semjonow A
Genes Chromosomes Cancer; 2008 Jul; 47(7):565-72. PubMed ID: 18383208
[TBL] [Abstract][Full Text] [Related]
6. Intraductal carcinoma of the prostate.
Szentirmai E; Giannico GA
Pathologica; 2020 Mar; 112(1):17-24. PubMed ID: 32202536
[TBL] [Abstract][Full Text] [Related]
7. Intraductal carcinoma of the prostate.
Robinson B; Magi-Galluzzi C; Zhou M
Arch Pathol Lab Med; 2012 Apr; 136(4):418-25. PubMed ID: 22458904
[TBL] [Abstract][Full Text] [Related]
8. Genomic and Evolutionary Characterization of Concurrent Intraductal Carcinoma and Adenocarcinoma of the Prostate.
Zhao J; Xu N; Zhu S; Nie L; Zhang M; Zheng L; Cai D; Sun X; Chen J; Dai J; Ni Y; Wang Z; Zhang X; Liang J; Chen Y; Hu X; Pan X; Yin X; Liu H; Zhao F; Zhang B; Chen H; Miao J; Qin C; Zhao X; Yao J; Liu Z; Liao B; Wei Q; Li X; Liu J; Gao AC; Huang H; Shen P; Chen N; Zeng H; Sun G
Cancer Res; 2024 Jan; 84(1):154-167. PubMed ID: 37847513
[TBL] [Abstract][Full Text] [Related]
9. Atypical Intraductal Cribriform Proliferations of the Prostate Exhibit Similar Molecular and Clinicopathologic Characteristics as Intraductal Carcinoma of the Prostate.
Hickman RA; Yu H; Li J; Kong M; Shah RB; Zhou M; Melamed J; Deng FM
Am J Surg Pathol; 2017 Apr; 41(4):550-556. PubMed ID: 28009609
[TBL] [Abstract][Full Text] [Related]
10. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.
Böttcher R; Kweldam CF; Livingstone J; Lalonde E; Yamaguchi TN; Huang V; Yousif F; Fraser M; Bristow RG; van der Kwast T; Boutros PC; Jenster G; van Leenders GJLH
BMC Cancer; 2018 Jan; 18(1):8. PubMed ID: 29295717
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate.
Zhao J; Sun G; Zhu S; Dai J; Chen J; Zhang M; Ni Y; Zhang H; Shen P; Zhao X; Zhang B; Pan X; Nie L; Yin X; Liang J; Zhang X; Wang Z; Zhu X; Liao B; Liu Z; Armstrong CM; Gao AC; Huang H; Chen N; Zeng H
BJU Int; 2022 Mar; 129(3):345-355. PubMed ID: 34185954
[TBL] [Abstract][Full Text] [Related]
12. Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management.
Shi Y; Wang H; Golijanin B; Amin A; Lee J; Sikov M; Hyams E; Pareek G; Carneiro BA; Mega AE; Lagos GG; Wang L; Wang Z; Cheng L
Urol Oncol; 2024 May; 42(5):144-154. PubMed ID: 38485644
[TBL] [Abstract][Full Text] [Related]
13. Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P).
Zhu S; Zhao J; Nie L; Yin W; Zhang Y; Zhao F; Ni Y; Zhang X; Wang Z; Dai J; Liu Z; Chen J; Zeng Y; Wang Z; Sun G; Liang J; Zhao X; Zhu X; Tao R; Yang J; He B; Chen N; Shen P; Zeng H
BMC Med; 2022 Jul; 20(1):237. PubMed ID: 35864546
[TBL] [Abstract][Full Text] [Related]
14. Genomic Features and Clinical Implications of Intraductal Carcinoma of the Prostate.
Kang M; Lee H; Byeon SJ; Kwon GY; Jeon SS
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884926
[TBL] [Abstract][Full Text] [Related]
15. Recent insights on the clinical, pathological, and molecular features of intraductal carcinoma of the prostate.
Naito Y; Kato M; Nagayama J; Sano Y; Matsuo K; Inoue S; Sano T; Ishida S; Matsukawa Y; Tsuzuki T; Akamatsu S
Int J Urol; 2024 Jan; 31(1):7-16. PubMed ID: 37728330
[TBL] [Abstract][Full Text] [Related]
16. A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma.
Cohen RJ; Wheeler TM; Bonkhoff H; Rubin MA
Arch Pathol Lab Med; 2007 Jul; 131(7):1103-9. PubMed ID: 17616999
[TBL] [Abstract][Full Text] [Related]
17. Premalignancy in Prostate Cancer: Rethinking What we Know.
De Marzo AM; Haffner MC; Lotan TL; Yegnasubramanian S; Nelson WG
Cancer Prev Res (Phila); 2016 Aug; 9(8):648-56. PubMed ID: 26813971
[TBL] [Abstract][Full Text] [Related]
18. Intraductal carcinoma of the prostate: What we know and what we do not know.
Chen X; Ding B; Zhang P; Geng S; Xu J; Han B
Pathol Res Pract; 2018 May; 214(5):612-618. PubMed ID: 29628124
[TBL] [Abstract][Full Text] [Related]
19. In-Depth Comparison of Genetic Variants Demonstrates a Close Relationship Between Invasive and Intraductal Components of Prostate Cancer.
Vormittag-Nocito E; Acosta AM; Agarwal S; Narayan KD; Kumar R; Al Rasheed MRH; Kajdacsy-Balla A; Behm FG; Mohapatra G
Mod Pathol; 2023 Jun; 36(6):100130. PubMed ID: 36933394
[TBL] [Abstract][Full Text] [Related]
20. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
